Guardant Health Shares Rise 7% After FDA Approves Its Blood Test For Colon Cancers

Category: Health

Guardant Health's shares surged 7% after FDA approval of its blood test, Shield, for colon cancer screening in adults 45 and older. This test aims to increase screening rates as many eligible Americans avoid traditional methods like colonoscopies due to their invasive nature. Shield is the first FDA-approved blood test for primary colon cancer screening and is covered by Medicare. Despite its effectiveness, screening rates remain below the national goal.

Keywords: Guardant Health, colon cancer, FDA approval

Source: Forbes

Update At: 7/30/2024

Related Sources